Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
|Articles|October 2, 2018
- Pharmaceutical Technology-10-02-2018
- Volume 42
- Issue 10
Pharmaceutical Technology North America, October 2018 (PDF)
Click to view Pharmaceutical Technology North America, October 2018 (PDF).
Advertisement
Articles in this issue
about 8 years ago
Drug Delivery Innovation Funded by the Gates Foundationabout 8 years ago
New Dose Forms Focus on the Patientabout 8 years ago
Protecting Solid-Dose Shelf Lifeabout 8 years ago
Considering Twin-Screw Granulationabout 8 years ago
Optimizing Containment in OSD Manufacturingabout 8 years ago
Developing Lipid-Based Formulationsabout 8 years ago
Efficiency Demands Drive Advances in API Labsabout 8 years ago
AAPS Traces the Path to ICH M10about 8 years ago
Outsourcing Development: Small-Scale to CommercialAdvertisement
Related to this article
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
3
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
4
Nitrosamine Problems and Industry Solutions: PharmTech Explained
5